Mesenchymal MAPKAPK2/HSP27 drives intestinal carcinogenesis

Area of Science:

• Oncology
• Cell Biology
• Molecular Biology

Background:

• Mesenchymal cells within the tumor microenvironment significantly influence cancer progression.
• Mitogen-activated protein kinase (MAPK) signaling pathways, including MAPKAPK2 (MK2), are implicated in tumorigenesis, but their cell-specific roles remain unclear.

Purpose of the Study:

• To investigate the cell-specific function of MK2 in intestinal carcinogenesis.
• To determine the role of MK2 in intestinal mesenchymal cells (IMCs) and its impact on tumor development.

Main Methods:

• Utilized complete and conditional ablation of MK2 in mouse models of intestinal carcinogenesis (Apcmin/+ and colitis-associated models).
• Assessed the effects of MK2 deletion in different cell types (mesenchymal, epithelial, endothelial) on tumor growth, proliferation, apoptosis, and angiogenesis.
• Investigated downstream molecular mechanisms, including Hsp27 phosphorylation.

Main Results:

• Complete or mesenchymal-specific MK2 inhibition reduced tumor multiplicity, growth, and invasiveness.
• MK2 in IMCs is crucial for Hsp27 phosphorylation and the production of factors affecting epithelial proliferation, apoptosis, and angiogenesis.
• Mesenchymal-specific MK2 inhibition was more effective than epithelial or endothelial-specific inhibition.
• MK2's role in IMCs was confirmed in both spontaneous and colitis-associated cancer models.

Conclusions:

• Mesenchymal MK2 plays a central pathogenic role in intestinal tumorigenesis, independent of immune cell modulation.
• The MK2/Hsp27 axis in mesenchymal cells is a key driver of tumor progression.
• Targeting mesenchymal MK2 presents a potential therapeutic strategy for cancer treatment.